MoonLake Immunotherapeutics (MLTX) Financial Statements
Free cash flow over the same period: -$225.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MLTXMoonLake ImmunotherapeuticsFollow MLTX — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | — | 42.0 | 31.8 | 112.8 | 202.9 | 221.4 | |
| Operating income | -4.6 | -65.1 | -54.1 | -143.1 | -244.8 | -268.3 | |
| Pre-tax income | — | -64.5 | -44.0 | -121.0 | -229.7 | -264.1 | |
| Income tax | — | 0.0 | 0.1 | 0.3 | 0.6 | 1.1 | |
| Net income | -4.5 | -50.0 | -36.0 | -118.9 | -227.3 | -263.7 | |
| Diluted EPS ($) | -0.31 | -1.70 | -0.73 | -1.89 | -3.53 | -3.57 | |
| Diluted shares (mn) | 360.0 | 29.4 | 49.1 | 62.9 | 64.5 | — |
USD millions · SEC XBRL
MoonLake Immunotherapeutics — questions
- What is MoonLake Immunotherapeutics's net income?
- -$263.7M over the twelve months to 2026-06-30.
- What is MoonLake Immunotherapeutics's free cash flow?
- -$225.2M over the twelve months to 2026-06-30.
- What are MoonLake Immunotherapeutics's diluted earnings per share?
- $-3.57 over the twelve months to 2026-06-30.
Every figure on this page comes from MoonLake Immunotherapeutics's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.